Petter Bjornstad
Concepts (341)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetic Nephropathies | 62 | 2023 | 234 | 21.540 |
Why?
| Diabetes Mellitus, Type 1 | 67 | 2022 | 3252 | 9.610 |
Why?
| Diabetes Mellitus, Type 2 | 47 | 2024 | 2094 | 8.120 |
Why?
| Glomerular Filtration Rate | 45 | 2024 | 604 | 6.160 |
Why?
| Uric Acid | 23 | 2022 | 148 | 4.920 |
Why?
| Kidney | 38 | 2024 | 1188 | 4.710 |
Why?
| Insulin Resistance | 17 | 2024 | 1072 | 3.970 |
Why?
| Albuminuria | 17 | 2022 | 164 | 2.980 |
Why?
| Renal Insufficiency, Chronic | 13 | 2023 | 486 | 2.790 |
Why?
| Metformin | 10 | 2023 | 276 | 2.750 |
Why?
| Coronary Artery Disease | 11 | 2022 | 607 | 2.750 |
Why?
| Pediatric Obesity | 7 | 2023 | 488 | 2.560 |
Why?
| Diabetic Angiopathies | 9 | 2019 | 244 | 2.550 |
Why?
| Bariatric Surgery | 5 | 2020 | 161 | 2.460 |
Why?
| Obesity, Morbid | 5 | 2020 | 197 | 2.360 |
Why?
| Glycopeptides | 10 | 2021 | 43 | 2.350 |
Why?
| Biomarkers | 28 | 2022 | 3408 | 2.320 |
Why?
| Vascular Calcification | 6 | 2022 | 107 | 2.220 |
Why?
| Renal Insufficiency | 5 | 2022 | 137 | 2.120 |
Why?
| Hemodynamics | 18 | 2022 | 1012 | 2.120 |
Why?
| Renin-Angiotensin System | 10 | 2021 | 72 | 2.040 |
Why?
| Hypoglycemic Agents | 16 | 2022 | 1012 | 1.930 |
Why?
| Adolescent | 52 | 2024 | 17837 | 1.810 |
Why?
| Cardiovascular Diseases | 13 | 2021 | 1727 | 1.620 |
Why?
| Humans | 133 | 2024 | 114654 | 1.520 |
Why?
| Sodium-Glucose Transporter 2 | 8 | 2022 | 17 | 1.420 |
Why?
| Male | 82 | 2024 | 55579 | 1.330 |
Why?
| Diabetic Ketoacidosis | 2 | 2022 | 159 | 1.330 |
Why?
| Calcinosis | 4 | 2015 | 242 | 1.330 |
Why?
| Young Adult | 36 | 2024 | 10465 | 1.300 |
Why?
| Creatinine | 12 | 2022 | 425 | 1.270 |
Why?
| Disease Progression | 16 | 2021 | 2380 | 1.260 |
Why?
| Female | 77 | 2024 | 59488 | 1.240 |
Why?
| Diabetic Cardiomyopathies | 4 | 2020 | 34 | 1.220 |
Why?
| Risk Factors | 33 | 2021 | 8631 | 1.180 |
Why?
| Hypertension | 9 | 2021 | 1056 | 1.110 |
Why?
| Sex Characteristics | 5 | 2020 | 640 | 1.070 |
Why?
| Adiposity | 4 | 2020 | 457 | 1.060 |
Why?
| Exercise Tolerance | 3 | 2017 | 213 | 1.050 |
Why?
| Atherosclerosis | 4 | 2018 | 341 | 1.030 |
Why?
| Adult | 47 | 2024 | 30542 | 1.010 |
Why?
| Fructose | 4 | 2021 | 100 | 1.000 |
Why?
| Apolipoproteins B | 2 | 2015 | 41 | 0.980 |
Why?
| Uromodulin | 3 | 2019 | 21 | 0.960 |
Why?
| Adiponectin | 2 | 2016 | 213 | 0.940 |
Why?
| Hyperuricemia | 6 | 2021 | 43 | 0.940 |
Why?
| Glucosides | 7 | 2022 | 36 | 0.930 |
Why?
| Benzhydryl Compounds | 7 | 2022 | 60 | 0.910 |
Why?
| Obesity | 10 | 2021 | 2508 | 0.890 |
Why?
| Follow-Up Studies | 15 | 2021 | 4411 | 0.890 |
Why?
| Vasopressins | 2 | 2021 | 56 | 0.890 |
Why?
| Middle Aged | 43 | 2022 | 26732 | 0.870 |
Why?
| Diabetic Retinopathy | 4 | 2021 | 149 | 0.860 |
Why?
| Vascular Stiffness | 6 | 2021 | 407 | 0.860 |
Why?
| Dyslipidemias | 5 | 2021 | 154 | 0.850 |
Why?
| Kidney Tubules | 2 | 2021 | 107 | 0.840 |
Why?
| Hyperoxia | 1 | 2024 | 99 | 0.840 |
Why?
| Child | 25 | 2023 | 18407 | 0.830 |
Why?
| Acute Kidney Injury | 4 | 2022 | 637 | 0.820 |
Why?
| Blood Glucose | 9 | 2019 | 1826 | 0.820 |
Why?
| Case-Control Studies | 13 | 2020 | 3003 | 0.820 |
Why?
| Arterioles | 2 | 2019 | 39 | 0.800 |
Why?
| Hyperglycemia | 4 | 2022 | 291 | 0.780 |
Why?
| Prognosis | 10 | 2021 | 3327 | 0.750 |
Why?
| Glucagon-Like Peptide-1 Receptor | 5 | 2022 | 72 | 0.720 |
Why?
| Oxygen Consumption | 3 | 2017 | 588 | 0.700 |
Why?
| Blood Pressure | 9 | 2022 | 1538 | 0.700 |
Why?
| Dried Blood Spot Testing | 2 | 2018 | 71 | 0.690 |
Why?
| Triglycerides | 3 | 2022 | 467 | 0.680 |
Why?
| Oxygen | 2 | 2024 | 854 | 0.680 |
Why?
| Iohexol | 2 | 2020 | 16 | 0.670 |
Why?
| Vascular Resistance | 6 | 2020 | 337 | 0.660 |
Why?
| Cyclic GMP | 1 | 2019 | 80 | 0.650 |
Why?
| Cross-Sectional Studies | 15 | 2019 | 4407 | 0.640 |
Why?
| Cystatin C | 6 | 2017 | 62 | 0.640 |
Why?
| Lipid Metabolism Disorders | 1 | 2018 | 2 | 0.640 |
Why?
| Coronary Vessels | 3 | 2017 | 227 | 0.630 |
Why?
| Weight Reduction Programs | 1 | 2019 | 94 | 0.620 |
Why?
| Gastric Bypass | 1 | 2020 | 92 | 0.620 |
Why?
| Leptin | 2 | 2017 | 210 | 0.620 |
Why?
| Longevity | 5 | 2019 | 137 | 0.610 |
Why?
| Incidence | 9 | 2021 | 2312 | 0.600 |
Why?
| Cardiotonic Agents | 1 | 2018 | 119 | 0.600 |
Why?
| Hemofiltration | 1 | 2018 | 31 | 0.600 |
Why?
| Sodium Bicarbonate | 1 | 2018 | 40 | 0.600 |
Why?
| Cholesterol, HDL | 2 | 2015 | 183 | 0.590 |
Why?
| Ventricular Function, Left | 3 | 2020 | 467 | 0.580 |
Why?
| Kidney Diseases | 2 | 2018 | 350 | 0.580 |
Why?
| Cohort Studies | 15 | 2019 | 4895 | 0.560 |
Why?
| Blood Vessels | 1 | 2018 | 180 | 0.560 |
Why?
| Aorta | 2 | 2019 | 386 | 0.550 |
Why?
| Glucose | 4 | 2022 | 896 | 0.550 |
Why?
| Kidney Failure, Chronic | 3 | 2021 | 489 | 0.540 |
Why?
| Nutrition Surveys | 1 | 2017 | 224 | 0.530 |
Why?
| Up-Regulation | 2 | 2016 | 807 | 0.530 |
Why?
| Cholesterol, LDL | 2 | 2014 | 307 | 0.530 |
Why?
| Kidney Function Tests | 4 | 2022 | 140 | 0.500 |
Why?
| Renal Circulation | 3 | 2021 | 53 | 0.490 |
Why?
| Hypoxia | 2 | 2020 | 957 | 0.480 |
Why?
| Pregnancy Outcome | 1 | 2017 | 337 | 0.480 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2014 | 7 | 0.470 |
Why?
| Echocardiography | 2 | 2018 | 553 | 0.460 |
Why?
| Dietary Supplements | 1 | 2018 | 460 | 0.460 |
Why?
| Overweight | 2 | 2018 | 471 | 0.450 |
Why?
| Goals | 1 | 2015 | 147 | 0.440 |
Why?
| Patient Care Planning | 1 | 2014 | 139 | 0.440 |
Why?
| Heart Failure | 3 | 2021 | 1945 | 0.430 |
Why?
| Canada | 6 | 2019 | 322 | 0.430 |
Why?
| Aged | 23 | 2022 | 19068 | 0.430 |
Why?
| Vasoconstriction | 3 | 2020 | 177 | 0.420 |
Why?
| Lipids | 2 | 2022 | 580 | 0.420 |
Why?
| Fasting | 1 | 2014 | 240 | 0.410 |
Why?
| Chitinase-3-Like Protein 1 | 2 | 2022 | 17 | 0.410 |
Why?
| Contrast Media | 1 | 2015 | 345 | 0.410 |
Why?
| Histidine | 2 | 2022 | 57 | 0.400 |
Why?
| Glucose Clamp Technique | 5 | 2020 | 181 | 0.380 |
Why?
| Clinical Trials as Topic | 6 | 2022 | 931 | 0.380 |
Why?
| Angiotensin II | 3 | 2020 | 87 | 0.370 |
Why?
| Guideline Adherence | 1 | 2015 | 490 | 0.360 |
Why?
| Body Mass Index | 8 | 2019 | 1958 | 0.360 |
Why?
| Pilot Projects | 5 | 2021 | 1373 | 0.360 |
Why?
| Sodium | 3 | 2022 | 183 | 0.350 |
Why?
| Lipocalin-2 | 2 | 2022 | 61 | 0.350 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 373 | 0.350 |
Why?
| Prospective Studies | 8 | 2020 | 6217 | 0.330 |
Why?
| Insulin | 5 | 2024 | 2078 | 0.330 |
Why?
| Albumins | 2 | 2022 | 89 | 0.320 |
Why?
| Kidney Glomerulus | 2 | 2021 | 100 | 0.310 |
Why?
| Diabetes Complications | 2 | 2021 | 211 | 0.290 |
Why?
| Metabolic Syndrome | 3 | 2021 | 321 | 0.290 |
Why?
| Treatment Outcome | 10 | 2019 | 9087 | 0.290 |
Why?
| Diabetes Mellitus | 3 | 2021 | 900 | 0.270 |
Why?
| Pulse Wave Analysis | 4 | 2021 | 207 | 0.270 |
Why?
| Severity of Illness Index | 3 | 2021 | 2537 | 0.270 |
Why?
| Age Factors | 7 | 2019 | 2894 | 0.270 |
Why?
| Colorado | 4 | 2017 | 4099 | 0.260 |
Why?
| Time Factors | 6 | 2018 | 6115 | 0.260 |
Why?
| Hydrogen-Ion Concentration | 2 | 2018 | 511 | 0.250 |
Why?
| Predictive Value of Tests | 4 | 2018 | 1796 | 0.250 |
Why?
| Early Diagnosis | 2 | 2017 | 217 | 0.240 |
Why?
| Lipoproteins | 2 | 2022 | 159 | 0.230 |
Why?
| Renin | 2 | 2022 | 31 | 0.230 |
Why?
| Body Composition | 2 | 2020 | 590 | 0.230 |
Why?
| Canagliflozin | 2 | 2021 | 8 | 0.220 |
Why?
| Consensus | 2 | 2022 | 537 | 0.210 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2020 | 44 | 0.200 |
Why?
| Malates | 1 | 2022 | 5 | 0.200 |
Why?
| Fumarates | 1 | 2022 | 10 | 0.200 |
Why?
| Carboxylic Acids | 1 | 2022 | 26 | 0.200 |
Why?
| Drug Therapy, Combination | 3 | 2019 | 951 | 0.200 |
Why?
| Threonine | 1 | 2022 | 40 | 0.200 |
Why?
| Natriuresis | 2 | 2019 | 8 | 0.200 |
Why?
| Phenylalanine | 1 | 2022 | 57 | 0.200 |
Why?
| Pathology, Clinical | 1 | 2022 | 32 | 0.200 |
Why?
| Chemokine CCL2 | 1 | 2022 | 105 | 0.190 |
Why?
| Leucine | 1 | 2022 | 102 | 0.190 |
Why?
| Glycine | 1 | 2022 | 152 | 0.190 |
Why?
| Arizona | 1 | 2021 | 68 | 0.190 |
Why?
| Tryptophan | 1 | 2022 | 136 | 0.190 |
Why?
| Glucagon-Like Peptide 1 | 1 | 2022 | 101 | 0.180 |
Why?
| Receptors, Vasopressin | 1 | 2021 | 18 | 0.180 |
Why?
| Longitudinal Studies | 4 | 2017 | 2387 | 0.180 |
Why?
| Osmolar Concentration | 2 | 2018 | 173 | 0.180 |
Why?
| p-Aminohippuric Acid | 1 | 2020 | 6 | 0.180 |
Why?
| Diuretics | 1 | 2021 | 66 | 0.180 |
Why?
| Multivariate Analysis | 2 | 2014 | 1430 | 0.180 |
Why?
| Furosemide | 1 | 2020 | 32 | 0.180 |
Why?
| Interleukin-18 | 1 | 2022 | 219 | 0.180 |
Why?
| Japan | 5 | 2017 | 86 | 0.180 |
Why?
| Natriuretic Peptide, Brain | 1 | 2021 | 94 | 0.180 |
Why?
| Nephrosis | 1 | 2020 | 4 | 0.180 |
Why?
| Asymptomatic Diseases | 2 | 2019 | 75 | 0.180 |
Why?
| Calcium Channel Blockers | 1 | 2021 | 114 | 0.180 |
Why?
| Diabetic Neuropathies | 1 | 2021 | 79 | 0.170 |
Why?
| Age of Onset | 1 | 2021 | 446 | 0.170 |
Why?
| Endothelin Receptor Antagonists | 1 | 2020 | 58 | 0.170 |
Why?
| Glycolysis | 1 | 2021 | 227 | 0.170 |
Why?
| Mineralocorticoid Receptor Antagonists | 1 | 2020 | 38 | 0.170 |
Why?
| Sodium-Glucose Transporter 1 | 1 | 2019 | 10 | 0.170 |
Why?
| Models, Biological | 3 | 2016 | 1620 | 0.170 |
Why?
| Body Water | 1 | 2019 | 19 | 0.170 |
Why?
| Diabetic Foot | 1 | 2019 | 22 | 0.170 |
Why?
| Glycosides | 1 | 2019 | 33 | 0.160 |
Why?
| Glomerulonephritis | 1 | 2019 | 45 | 0.160 |
Why?
| Postmenopause | 1 | 2021 | 303 | 0.160 |
Why?
| Blood Chemical Analysis | 1 | 2019 | 90 | 0.160 |
Why?
| Body Temperature Regulation | 1 | 2019 | 72 | 0.160 |
Why?
| Weight Loss | 2 | 2020 | 642 | 0.160 |
Why?
| beta 2-Microglobulin | 1 | 2018 | 45 | 0.160 |
Why?
| Myocardial Contraction | 1 | 2020 | 313 | 0.160 |
Why?
| Carotid Intima-Media Thickness | 1 | 2018 | 65 | 0.160 |
Why?
| Amino Acids | 1 | 2022 | 448 | 0.160 |
Why?
| Microscopy, Polarization | 1 | 2018 | 30 | 0.150 |
Why?
| Biopsy | 1 | 2022 | 1036 | 0.150 |
Why?
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 35 | 0.150 |
Why?
| Allopurinol | 1 | 2018 | 53 | 0.150 |
Why?
| Pharmaceutical Preparations | 1 | 2020 | 165 | 0.150 |
Why?
| Obesity, Metabolically Benign | 1 | 2017 | 4 | 0.150 |
Why?
| Heat Stress Disorders | 1 | 2018 | 40 | 0.150 |
Why?
| Glucose Tolerance Test | 2 | 2019 | 343 | 0.150 |
Why?
| Prehypertension | 1 | 2017 | 24 | 0.150 |
Why?
| Glomerulosclerosis, Focal Segmental | 1 | 2017 | 29 | 0.140 |
Why?
| Hyperthermia, Induced | 1 | 2018 | 65 | 0.140 |
Why?
| Tomography, X-Ray Computed | 2 | 2018 | 2285 | 0.140 |
Why?
| Life Style | 1 | 2019 | 430 | 0.140 |
Why?
| Precision Medicine | 1 | 2020 | 337 | 0.140 |
Why?
| Running | 1 | 2019 | 207 | 0.140 |
Why?
| Urinary Calculi | 1 | 2017 | 11 | 0.140 |
Why?
| Peptide Fragments | 1 | 2021 | 666 | 0.140 |
Why?
| Cardiorespiratory Fitness | 1 | 2017 | 35 | 0.140 |
Why?
| Magnetic Resonance Angiography | 1 | 2018 | 220 | 0.140 |
Why?
| Regional Blood Flow | 1 | 2018 | 424 | 0.140 |
Why?
| Vasodilation | 1 | 2020 | 419 | 0.140 |
Why?
| Morbidity | 1 | 2017 | 280 | 0.140 |
Why?
| Survival Rate | 2 | 2017 | 1644 | 0.140 |
Why?
| Ventricular Dysfunction, Left | 1 | 2020 | 358 | 0.140 |
Why?
| Blood Banks | 1 | 2016 | 40 | 0.140 |
Why?
| Anti-Inflammatory Agents | 1 | 2020 | 447 | 0.140 |
Why?
| Hot Temperature | 1 | 2018 | 302 | 0.130 |
Why?
| Logistic Models | 3 | 2017 | 1840 | 0.130 |
Why?
| Animals | 10 | 2021 | 31698 | 0.130 |
Why?
| Vitreoretinopathy, Proliferative | 1 | 2016 | 10 | 0.130 |
Why?
| Heart Rate | 1 | 2019 | 709 | 0.130 |
Why?
| Linear Models | 2 | 2017 | 768 | 0.130 |
Why?
| Disease Models, Animal | 4 | 2021 | 3531 | 0.130 |
Why?
| Double-Blind Method | 1 | 2020 | 1660 | 0.130 |
Why?
| Software | 1 | 2019 | 530 | 0.130 |
Why?
| Echocardiography, Doppler | 1 | 2016 | 92 | 0.130 |
Why?
| Liver Diseases | 1 | 2018 | 255 | 0.120 |
Why?
| Risk Assessment | 4 | 2019 | 2968 | 0.120 |
Why?
| Absorptiometry, Photon | 1 | 2016 | 224 | 0.120 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 179 | 0.120 |
Why?
| Child, Preschool | 2 | 2022 | 9111 | 0.120 |
Why?
| Filtration | 1 | 2015 | 59 | 0.120 |
Why?
| Phenotype | 1 | 2022 | 2796 | 0.120 |
Why?
| Enzyme Inhibitors | 1 | 2018 | 750 | 0.120 |
Why?
| Apolipoproteins | 1 | 2014 | 36 | 0.120 |
Why?
| Blood Pressure Determination | 1 | 2015 | 122 | 0.120 |
Why?
| Purines | 1 | 2015 | 159 | 0.110 |
Why?
| Immunity, Innate | 1 | 2019 | 720 | 0.110 |
Why?
| Liver | 2 | 2021 | 1637 | 0.110 |
Why?
| Achievement | 1 | 2014 | 54 | 0.110 |
Why?
| Stress, Mechanical | 1 | 2016 | 445 | 0.110 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2019 | 1214 | 0.110 |
Why?
| Research Design | 1 | 2019 | 928 | 0.110 |
Why?
| Exercise Test | 1 | 2016 | 544 | 0.110 |
Why?
| Primary Prevention | 1 | 2015 | 172 | 0.110 |
Why?
| Biomechanical Phenomena | 1 | 2016 | 668 | 0.110 |
Why?
| Aged, 80 and over | 3 | 2018 | 6345 | 0.110 |
Why?
| Adenosine Triphosphate | 1 | 2015 | 430 | 0.110 |
Why?
| Cholesterol | 1 | 2014 | 367 | 0.100 |
Why?
| Antihypertensive Agents | 1 | 2016 | 429 | 0.100 |
Why?
| RNA, Messenger | 1 | 2019 | 2552 | 0.100 |
Why?
| Feasibility Studies | 1 | 2015 | 740 | 0.100 |
Why?
| Testosterone | 1 | 2015 | 343 | 0.100 |
Why?
| Regression Analysis | 1 | 2014 | 944 | 0.100 |
Why?
| Ambulatory Care | 1 | 2015 | 478 | 0.090 |
Why?
| Societies, Medical | 1 | 2015 | 663 | 0.090 |
Why?
| United States | 2 | 2017 | 12179 | 0.090 |
Why?
| Vascular Diseases | 1 | 2013 | 230 | 0.090 |
Why?
| Gene Expression Regulation | 1 | 2019 | 2319 | 0.090 |
Why?
| Hematocrit | 2 | 2021 | 87 | 0.090 |
Why?
| Practice Guidelines as Topic | 1 | 2017 | 1394 | 0.090 |
Why?
| Registries | 1 | 2016 | 1767 | 0.080 |
Why?
| Inflammation | 2 | 2021 | 2478 | 0.080 |
Why?
| Prevalence | 3 | 2019 | 2250 | 0.080 |
Why?
| Reproducibility of Results | 1 | 2015 | 2762 | 0.070 |
Why?
| Sex Factors | 3 | 2017 | 1715 | 0.070 |
Why?
| Rats | 1 | 2015 | 4958 | 0.070 |
Why?
| Retrospective Studies | 6 | 2019 | 12544 | 0.070 |
Why?
| Pregnancy | 1 | 2017 | 5517 | 0.060 |
Why?
| Aging | 1 | 2014 | 1618 | 0.060 |
Why?
| Infant, Newborn | 1 | 2014 | 5044 | 0.060 |
Why?
| Mice | 2 | 2021 | 14863 | 0.060 |
Why?
| Cytokines | 2 | 2021 | 1840 | 0.050 |
Why?
| Benzbromarone | 1 | 2022 | 2 | 0.050 |
Why?
| Aldosterone | 1 | 2022 | 42 | 0.050 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2021 | 27 | 0.050 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2021 | 82 | 0.050 |
Why?
| Infant | 1 | 2014 | 7959 | 0.050 |
Why?
| Inulin | 1 | 2021 | 6 | 0.050 |
Why?
| Fructokinases | 1 | 2021 | 29 | 0.050 |
Why?
| Drinking | 1 | 2021 | 33 | 0.050 |
Why?
| Hep G2 Cells | 1 | 2021 | 60 | 0.050 |
Why?
| Serum Albumin | 1 | 2021 | 137 | 0.050 |
Why?
| Uricosuric Agents | 1 | 2020 | 1 | 0.050 |
Why?
| Diuretics, Osmotic | 1 | 2020 | 1 | 0.040 |
Why?
| Cell Hypoxia | 1 | 2021 | 220 | 0.040 |
Why?
| Mendelian Randomization Analysis | 1 | 2020 | 43 | 0.040 |
Why?
| Mice, Inbred C57BL | 2 | 2021 | 4692 | 0.040 |
Why?
| Diastole | 1 | 2020 | 130 | 0.040 |
Why?
| Systole | 1 | 2020 | 171 | 0.040 |
Why?
| Netherlands | 1 | 2019 | 64 | 0.040 |
Why?
| Chemokines | 1 | 2021 | 216 | 0.040 |
Why?
| Cytoprotection | 1 | 2019 | 51 | 0.040 |
Why?
| Drug Interactions | 1 | 2021 | 338 | 0.040 |
Why?
| Preoperative Period | 1 | 2019 | 103 | 0.040 |
Why?
| Magnetic Resonance Imaging, Cine | 1 | 2020 | 172 | 0.040 |
Why?
| Fibrosis | 1 | 2021 | 453 | 0.040 |
Why?
| Incretins | 1 | 2018 | 15 | 0.040 |
Why?
| Macular Edema | 1 | 2018 | 34 | 0.040 |
Why?
| Photography | 1 | 2018 | 89 | 0.040 |
Why?
| Renal Elimination | 1 | 2018 | 6 | 0.040 |
Why?
| Inflammation Mediators | 1 | 2021 | 477 | 0.040 |
Why?
| Xanthine Oxidase | 1 | 2018 | 71 | 0.040 |
Why?
| Renal Dialysis | 1 | 2021 | 374 | 0.040 |
Why?
| HSP70 Heat-Shock Proteins | 1 | 2018 | 61 | 0.040 |
Why?
| Proof of Concept Study | 1 | 2017 | 47 | 0.040 |
Why?
| Diet Therapy | 1 | 2018 | 36 | 0.040 |
Why?
| Tomography, Optical Coherence | 1 | 2018 | 130 | 0.040 |
Why?
| Anti-Obesity Agents | 1 | 2018 | 45 | 0.040 |
Why?
| Proteinuria | 1 | 2017 | 77 | 0.040 |
Why?
| Cardiovascular System | 1 | 2019 | 125 | 0.040 |
Why?
| Lipoproteins, LDL | 1 | 2017 | 128 | 0.040 |
Why?
| Blood Pressure Monitoring, Ambulatory | 1 | 2017 | 61 | 0.040 |
Why?
| Renal Plasma Flow, Effective | 1 | 2016 | 1 | 0.040 |
Why?
| Interleukin-6 | 1 | 2021 | 676 | 0.030 |
Why?
| Infusions, Intravenous | 1 | 2018 | 371 | 0.030 |
Why?
| Thiazolidinediones | 1 | 2018 | 142 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2019 | 1075 | 0.030 |
Why?
| Age Distribution | 1 | 2017 | 342 | 0.030 |
Why?
| Sex Distribution | 1 | 2017 | 337 | 0.030 |
Why?
| Collagen | 1 | 2018 | 415 | 0.030 |
Why?
| Waist Circumference | 1 | 2015 | 122 | 0.030 |
Why?
| Blood Glucose Self-Monitoring | 1 | 2019 | 504 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2018 | 1121 | 0.030 |
Why?
| Circadian Rhythm | 1 | 2017 | 354 | 0.030 |
Why?
| Mice, Knockout | 1 | 2021 | 2568 | 0.030 |
Why?
| Exercise Therapy | 1 | 2018 | 351 | 0.030 |
Why?
| Heart Ventricles | 1 | 2018 | 712 | 0.030 |
Why?
| Peptides | 1 | 2018 | 848 | 0.030 |
Why?
| Rats, Sprague-Dawley | 1 | 2017 | 2218 | 0.030 |
Why?
| Comorbidity | 1 | 2017 | 1448 | 0.030 |
Why?
| Databases, Factual | 1 | 2017 | 1125 | 0.030 |
Why?
| Gene-Environment Interaction | 1 | 2014 | 183 | 0.030 |
Why?
| Models, Statistical | 1 | 2015 | 599 | 0.020 |
Why?
| Non-alcoholic Fatty Liver Disease | 1 | 2014 | 245 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2020 | 3044 | 0.020 |
Why?
| Hospitalization | 1 | 2017 | 1750 | 0.020 |
Why?
| Algorithms | 1 | 2015 | 1467 | 0.020 |
Why?
| Neoplasms | 1 | 2014 | 2097 | 0.010 |
Why?
|
|
Bjornstad's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|